Ovid Therapeutics Inc. (OVID)
| Market Cap | 225.60M |
| Revenue (ttm) | 473,535 |
| Net Income (ttm) | -50.68M |
| Shares Out | 70.94M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | 1.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 748 |
| Open | 3.150 |
| Previous Close | 3.150 |
| Day's Range | 3.110 - 3.305 |
| 52-Week Range | 2.570 - 4.139 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 7.75 (+146.03%) |
| Earnings Date | May 14, 2024 |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex an... [Read more]
Financial Performance
In 2023, OVID's revenue was $391,695, a decrease of -73.93% compared to the previous year's $1.50 million. Losses were -$52.34 million, -3.38% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price forecast is $7.75, which is an increase of 146.03% from the latest price.
News
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and br...
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of ...
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and ...
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and ...
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies...
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026
NEW YORK and SAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of people with r...
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and ...
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and ...
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies...
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and ...
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies...
Ovid Therapeutics Added to Russell 3000® Index
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
NEW YORK, May 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies ...
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) reports that Takeda Pharmaceuticals presented interim data at the 2023 annual meeting of the American Academy of Neur...
Texas abortion pill decision ‘threatens the health of America,' Ovid Therapeutics CEO says
Ovid Therapeutics CEO Jeremy Levin joins Yahoo Finance Live's Anjalee Khemlani to discuss a Texas judge's ruling on an abortion pill ban, drugmakers opposing the decision, uncertainty for pharmaceutic...
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies an...
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...